Quest Diagnostics Incorporated has announced the launch of its first ctDNA minimal residual disease $(MRD.AU)$ test, Haystack MRD™, aimed at improving cancer monitoring for patients treated for solid tumors. The launch comes as part of a response to the increasing prevalence of advanced-stage cancers and the associated challenges in early detection of cancer recurrence. A recent survey conducted by The Harris Poll on behalf of Quest Diagnostics highlights that 76% of oncologists are observing more advanced cancers, with 94% believing that ctDNA MRD testing could significantly reduce delays in diagnosing cancer recurrence. Despite the promise of these new tests, oncologists acknowledge hurdles to their wide adoption. The Haystack MRD™ test is part of Quest Diagnostics' efforts to provide innovative solutions amid growing concerns of cancer recurrence among survivors, expected to reach 26 million by 2040.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.